baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Bellerophon Therapeutics/ US0787713009 /

13/10/2023 21:59:59	Chg. -	Volume	Bid01:59:05	Ask01:59:46	High	Low
0.1025USD	-	14.95 mill. Turnover: 1.44 mill.	0.1100Bid Size: 12,700	0.1150Ask Size: 7,700	0.3030	0.0760

GlobeNewswire 26/12/2023 Delisting of Securities of SmileDirectClub, Inc.; Bellerophon Therapeutics, Inc.; Elys Game Technolo...

GlobeNewswire 10/01/2022 Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference

GlobeNewswire 17/12/2021 Bellerophon Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of INOpulse® for...

GlobeNewswire 15/11/2021 Bellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial Results

GlobeNewswire 07/09/2021 Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire 05/08/2021 Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results

GlobeNewswire 27/05/2021 Bellerophon to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire 26/05/2021 Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors

GlobeNewswire 11/05/2021 Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results

GlobeNewswire 11/03/2021 Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2020 Financial...

GlobeNewswire 02/03/2021 Bellerophon to Present at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire 04/01/2021 Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

GlobeNewswire 30/12/2020 Ekso Bionics’ Stockholders Elect Mary Ann Cloyd and Rhonda A. Wallen to its Board of Directors

GlobeNewswire 01/12/2020 Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpul...

GlobeNewswire 23/11/2020 Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse®...

GlobeNewswire 11/11/2020 Bellerophon to Present at the H.C. Wainwright 6th Annual Israel Conference

GlobeNewswire 05/11/2020 Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial Results

GlobeNewswire 29/10/2020 Bellerophon to Present Results from its Phase 2 iNO-PF Study of INOpulse® for the Treatment of Fibro...

GlobeNewswire 14/09/2020 Bellerophon to Present at Two September Investor Conferences

GlobeNewswire 11/08/2020 Bellerophon Appoints Cardiopulmonary Disease Expert Wassim Fares, M.D., MSCR, as Chief Medical Offic...

GlobeNewswire 05/08/2020 Bellerophon Provides Clinical Program Update and Reports Second Quarter 2020 Financial Results

GlobeNewswire 15/07/2020 Bellerophon Therapeutics Announces Publication of Cohort 1 of iNO-PF Phase 2/3 Study in the CHEST Jo...

GlobeNewswire 13/07/2020 Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inha...

GlobeNewswire 29/06/2020 Bellerophon Therapeutics Added to Russell 3000® and Microcap® Indexes

GlobeNewswire 25/05/2020 Kalytera Issues CEO Letter to Shareholders

Bellerophon Therapeutics/ US0787713009 /

If you wish to receive reply to your feedback, please provide your email address.